Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigational higher-dose dulaglutide versus dulaglutide 1.5 mg in type 2 diabetes on metformin
2017-003490-33Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dulaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline. Started Mar 2018; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-003490-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003490-33.